MX2023007103A - Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas. - Google Patents

Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas.

Info

Publication number
MX2023007103A
MX2023007103A MX2023007103A MX2023007103A MX2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A
Authority
MX
Mexico
Prior art keywords
receptor binding
tetravalent
fzd
wnt
antibody molecules
Prior art date
Application number
MX2023007103A
Other languages
English (en)
Spanish (es)
Inventor
Somasekar Seshagiri
Sachdev Sidhu
Jarrett Adams
Stephane H Angers
Levi Blazer
Original Assignee
Antlera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antlera Therapeutics Inc filed Critical Antlera Therapeutics Inc
Publication of MX2023007103A publication Critical patent/MX2023007103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023007103A 2020-12-18 2021-12-17 Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas. MX2023007103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127408P 2020-12-18 2020-12-18
PCT/IB2021/061972 WO2022130342A1 (en) 2020-12-18 2021-12-17 Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2023007103A true MX2023007103A (es) 2023-06-27

Family

ID=82058983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007103A MX2023007103A (es) 2020-12-18 2021-12-17 Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas.

Country Status (11)

Country Link
US (3) US20250270332A1 (enExample)
EP (3) EP4263618A4 (enExample)
JP (3) JP2024500839A (enExample)
KR (1) KR20230122077A (enExample)
CN (2) CN116917332A (enExample)
AU (2) AU2021399278A1 (enExample)
CA (2) CA3204321A1 (enExample)
CL (2) CL2023001768A1 (enExample)
IL (2) IL303344A (enExample)
MX (1) MX2023007103A (enExample)
WO (2) WO2022130342A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
KR20220024460A (ko) * 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
CR20240266A (es) * 2021-12-31 2024-11-11 Surrozen Operating Inc Compuesto específico de receptor wnt y método relacionado con este
EP4547713A4 (en) * 2022-06-30 2026-07-08 Univ Chicago CD73 Targeting Polypeptides (NT5E)
WO2024227103A1 (en) * 2023-04-27 2024-10-31 Surrozen Operating, Inc. Molecules modulating wnt signaling pathways and uses thereof
WO2025019458A2 (en) * 2023-07-14 2025-01-23 The Trustees Of Columbia University In The City Of New York Specific blood retinal barrier defect in glaucoma directs new treatments and clinical tests
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
US20260070966A1 (en) * 2024-09-06 2026-03-12 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof
US20260092125A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
SG10201601747XA (en) 2012-01-18 2016-04-28 Genentech Inc Anti-LRP5 Antibodies And Methods Of Use
DE102012202081A1 (de) 2012-02-13 2013-08-14 Osram Gmbh Glühfaden für elektrische lampen und elektrische lampe sowie herstellungsverfahren für einen glühfaden
WO2014161037A1 (en) 2013-04-03 2014-10-09 Peter Maccallum Cancer Institute Antibodies against human ryk and uses therefor
US9237411B2 (en) 2013-07-25 2016-01-12 Elwha Llc Systems and methods for providing one or more functionalities to a wearable computing device with directional antenna
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2017127933A1 (en) 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
WO2018026942A1 (en) 2016-08-02 2018-02-08 Merrimack Pharmaceuticals, Inc. Heteromeric polypeptides
US11039659B2 (en) 2017-09-07 2021-06-22 Nike, Inc. Sole structure for article of footwear
US20210032352A1 (en) 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
AU2019297522B2 (en) * 2018-07-05 2026-04-23 Surrozen Operating, Inc. Multi-specific Wnt surrogate molecules and uses thereof
US10671121B2 (en) 2018-09-14 2020-06-02 Apple Inc. Magnetic layout in electronic devices and accessory devices for electronic devices
KR20220024460A (ko) * 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도

Also Published As

Publication number Publication date
AU2021399278A1 (en) 2023-06-29
AU2021404080A1 (en) 2023-06-29
CL2025001491A1 (es) 2025-08-22
CA3204321A1 (en) 2022-06-23
JP2024500839A (ja) 2024-01-10
CN116917332A (zh) 2023-10-20
US20230118983A1 (en) 2023-04-20
EP4543921A2 (en) 2025-04-30
US20240228631A9 (en) 2024-07-11
JP2023554500A (ja) 2023-12-27
CN116964102A (zh) 2023-10-27
CA3204322A1 (en) 2022-06-23
US20240132600A1 (en) 2024-04-25
KR20230122077A (ko) 2023-08-22
EP4263617A4 (en) 2025-01-01
US20250270332A1 (en) 2025-08-28
EP4263618A1 (en) 2023-10-25
EP4263617A1 (en) 2023-10-25
WO2022130341A1 (en) 2022-06-23
WO2022130342A1 (en) 2022-06-23
CL2023001768A1 (es) 2024-01-12
EP4263618A4 (en) 2024-11-20
IL303344A (en) 2023-08-01
JP2026041774A (ja) 2026-03-10
JP7778148B2 (ja) 2025-12-01
WO2022130342A4 (en) 2022-08-11
IL303342A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CL2025001491A1 (es) Moléculas de anticuerpos de unión tetravalentes y usos de las mismas
AU2021404080A9 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
AU2021399278A9 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
CL2021002370A1 (es) Mezclado controlado de fracciones de transmezcla en corrientes de hidrocarburo definidas
EP3871217A4 (en) METHOD AND DEVICE FOR ADJUSTING AUDIO PLAYBACK SETTINGS BASED ON ANALYSIS OF AUDIO CHARACTERISTICS
BR112018013677A2 (pt) proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
MX389547B (es) Moleculas de union que inhibe el crecimiento de cancer.
BR112019003976A2 (pt) anticorpos anti-tim-3 e seu uso
BR112018013911A2 (pt) proteínas de fusão de ligação a ox40 multivalentes e multiespecíficas
AR106574A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
MX2021015439A (es) Moleculas multivalentes de union a fzd y wnt y usos de las mismas.
NZ724815A (en) Humanized antibodies that bind lgr5
MX2010004726A (es) Antigeno asociado con artritis reumatoide.
EP3872417A4 (en) PRE-COOLING DEVICE FOR CRYOTHERAPY AND CRYOTHERAPY SYSTEM
GB2513559A8 (en) Unknown speaker identification system
BR112018067851A2 (pt) composições e métodos para o tratamento de artrite reumatoide
BR112015013771A8 (pt) preditividade por biomarcadores da resposta a tratamentos com ativadores do receptor alfa 7 nicotínico de acetilcolina
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
AR073140A1 (es) Anticuerpos anti-il-23r disenados
CL2022000272S1 (es) Soporte para dispositivo de prueba.
CO2019002751A2 (es) Composiciones marcadoras, y metodos para fabricar y usar las mismas
EP3804850A4 (en) HYDROCARBON REFORMING CATALYST AND HYDROCARBON REFORMING DEVICE
WO2023250402A3 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
MX2021000786A (es) Receptor para supresor de ig del dominio v de activación de células t (vista).
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso